Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is expected to report third quarter earnings results, after market close, on Monday 9th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.19 per share.
Looking ahead, the full year loss are expected at $ 1.49 per share on the revenues of $ 5.91 million.
Previous Quarter Performance
Inovio Pharmaceuticals, Inc. outlined loss for the second quarter of $ 0.20 per share, from the revenue of $ 0.27 million. The quarterly revenues gained 92.86 percent compared with the same quarter last year. According to street consensus, INO was expected to report 2Q20 loss of $ 0.17 per share from revenue of $ 2.61 million. The bottom line results missed street analysts by $ 0.03 or 17.65 percent, at the same time, top line results fell short of analysts by $ 2.34 million or 89.66 percent.
Stock Performance
On Friday, shares of Inovio Pharmaceuticals, Inc. has traded high as $ 10.67 and has cracked $ 10.26 on the downward trend, reaching $ 10.53 with volume of 4.71 million shares.
According to the previous trading day, closing price of $ 10.53, representing a 393.15 % increase from the 52 week low of $ 2.19 and a 68.04 % decrease over the 52 week high of $ 33.79.
The company has a market capital of $ 1.76 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 28th September 2020, upgraded by Maxim Group to Buy from Hold rating.
- On 28th September 2020, downgraded by Cantor Fitzgerald to Neutral from Overweight rating, with $ 12.00 target price.
Conference Call
Inovio Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.inovio.com
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune systems tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus.
